Resources

The current International Space Station (ISS) method for dealing with medical emergencies is to return astronauts to Earth as soon as possible. As a plan A it’s obviously incredibly difficult, expensive and unpredictable to say the least, and as missions are set...

Molecular diagnostics maker Biocept has launched a new multi-gene liquid biopsy test called Target Selector NGS Lung Panel, for the detection of lung cancer. The company’s Target Selector liquid biopsy platform is designed to capture and analyse...

Breath Biopsy solutions provider Owlstone Medical has partnered with Actelion Pharmaceuticals to discover and validate a breath test for the early diagnosis of pulmonary hypertension (PH) and its subtypes. Funded by Actelion, the alliance will involve collection of...

Varian Medical Systems, a radiation oncology treatment solutions provider, has signed a definitive agreement to acquire Cancer Treatment Services International (CTSI) for $283m. CTSI runs the American Oncology Institute in Hyderabad, India along with ten...

The US Food and Drug Administration (FDA) recently posted a safety warning stating that off-label use of Stryker’s Wingspan stent system could increase the risk of stroke or death. This warning came on 25 April, shortly after results from a mandated post-market...

The past week’s biotech discoveries included a compound in cruciferous vegetables that suppresses a cancer-causing gene mutation; 14 chemicals in ragweed that may combat amyloid buildup in Alzheimer’s; and a new protein target in Parkinson’s.

The Medicines Company announced long-term data for its Alnylam-partnered inclisiran, showing that the drug consistently lowered “bad” LDL cholesterol by more than 50%. If approved, the twice-a-year injection will compete with anti-PCSK9 drugs from Amgen,...

J&J was ordered by a Philadelphia jury to pay $80 million to a woman whose vaginal mesh eroded, on the heels of a $120 million verdict issued against the company's Ethicon unit last month.

Gary Pisano’s recent Harvard Business Review piece, The Hard Truth About Innovative Cultures, beautifully frames up how innovative corporate environments are frequently misunderstood. Innovative startups aren’t just about being cool and nimble, having...

Schrödinger has raised more money, bringing the total size of its recent haul up to $110 million. The computing-enabled R&D shop will use the money to advance its nascent pipeline of wholly owned drugs.

Arrhythmia-focused Acutus Medical is moving to acquire catheter developer Rhythm Xience while launching a handful of new strategic partnerships as it looks to expand its portfolio beyond its heart mapping and visualization platform.

Vertex Pharmaceuticals is paying $70 million upfront to work with Kymera Therapeutics on the discovery of drugs that drive the elimination of disease-causing proteins. The early-stage deal features more than $1 billion in milestones tied to the success of six...

Translation of well validated biology into therapeutics remains one of the biggest challenges of modern drug development, in many cases due to lack of appropriate technologies to drug well credentialed biological targets. Examples in this category include driver...

The IQVIA Institute released a data-rich report in April 2019 on the state of clinical R&D in the US pharmaceutical industry titled “The Changing Landscape of Research and Development: Innovation, Drivers of Change, and Evolution of Clinical Trial...

It is with great excitement that we at Nimbus are ringing in our 10th birthday this month. It’s been a momentous decade of ups and downs, many of them chronicled in dozens of posts here on LifeSciVC. At 10 years and still going, we’re proud to...

Startups management teams often have a love-hate relationship with their Board of Directors: while Boards can be hugely helpful and constructive in the best of times, they can be dysfunctional and damaging in the worst. And most CEOs enjoy complaining about their...

Recently I read the article What’s Wrong With Me? that I saw re-posted on Twitter.  It’s a 2013 New Yorker article chronicling one woman’s journey through years of multi-symptom autoimmune/autoinflammatory disease with undiagnosed and...

“It takes twenty years to build a reputation, and five minutes to ruin it,” Warren Buffett said, and added “If you think about that, you’ll do things differently.” In biotech, a strong reputation is difficult to build, is even harder to...

Obsidian Therapeutics has named Paul Wotton as CEO. The appointment gives Obsidian a full-time CEO following a period in which Michael Gilman helmed the biotech while also running Arrakis Therapeutics. Read more.

Check out the April 8 Beyond Clean podcast featuring Peter Nichol on the $50 billion dollar savings opportunity that exists by investing in Sterile Processing departments.  Dr. Nichol’s discusses his research facing sterile processing departments...